XXA1_Y4eK-BH3

General Information


DRACP ID  DRACP03032

Peptide Name   XXA1_Y4eK-BH3

Sequence  RPEIWYAQGLKRFGDEFNAYKAR

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Induce apoptosis Bcl-xL inhibitors BH3 peptides and mimetics



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MDA-MB-231 (Bc1-xL dependent) Breast adenocarcinoma Carcinoma EC50=82 ± 27 nM Not available Not available 1
OCI-Ly1 (Bcl-2 dependent) Diffuse large B-cell lymphoma Lymphoma EC50=911 ± 222 nM Not available Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Bcl-xL

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03032

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C130H191N37O34

Absent amino acids  CHMSTV

Common amino acids  AR

Mass  320876

Pl  9.93

Basic residues  5

Acidic residues  3

Hydrophobic residues  8

Net charge  2

Boman Index  -6522

Hydrophobicity  -110.43

Aliphatic Index  46.96

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  8480

Absorbance 280nm  385.45

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25451027

Title  Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL

Doi 10.1016/j.jmb.2014.09.030

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.